Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Consumer IPOs from Snap to Uber have been disappointing and serve as a reminder that private investors are making all the money.Technologyread more
The company's comments Friday come after the White House said U.S.Trade Representative Robert Lighthizer will "address the threatened impairment" of national security from...Autosread more
China's currency has been an important barometer for progress in U.S.-Chinese trade talks, and right now it's signaling things aren't going well.Market Insiderread more
Some analysts see streaming services like Netflix becoming hindered by one of the things that made them so popular in the first place — binge watching.Entertainmentread more
Apple CEO Tim Cook was the commencement speaker at Tulane University Saturday. In his speech, the tech executive focused on the importance of addressing climate change and...Power Playersread more
There is a shortfall of cybersecurity workers that could reach as high as 3.5 million unfilled roles by 2021. A start-up called Synack provides crowdsourced security, and...CNBC Disruptor 50read more
Yardeni Research's Edward Yardeni recommends investing in U.S. companies with exposure to China.Trading Nationread more
CNBC and SurveyMonkey's latest small business optimism index echoes that sentiment, finding 52 percent of small businesses say it's harder to find workers today than it was a...US Economyread more
CNBC combed through Wall Street research over the last week to see which stocks analysts say have the best risk-reward.Marketsread more
Western Union is not panicking, but the delivery of money around the world is being upended, says CEO of upstart TransferWise. It broke into the $689 billion remittances...CNBC Disruptor 50read more
The former chief executive of Insys Therapeutics is expected on Wednesday to plead guilty to participating in a scheme to pay doctors bribes in exchange for prescribing an addictive opioid medication.
Michael Babich, who resigned as the Arizona-based drugmaker's CEO in 2015, is scheduled to appear in federal court in Boston and plead guilty to conspiracy and mail fraud charges, according to court papers.
His plea comes weeks before a five former Insys executives and managers including John Kapoor, the company's founder and former chairman, are scheduled to face trial over what prosecutors said was their roles in the wide-ranging scheme.
The terms of Babich's plea deal have not been disclosed, leaving it unclear whether he has agreed to cooperate with prosecutors and testify at that trial. Kapoor and his co-defendants have pleaded not guilty to racketeering conspiracy.
Insys in August said it had agreed to settle a related U.S. Justice Department probe for at least $150 million. The company has said it is now under new management, which has taken steps to ensure it operates legally going forward.
Babich's attorney declined to comment.
The case centers on Subsys, Insys' under-the-tongue spray for managing severe pain in cancer patients. It contains fentanyl, an opioid 100 times stronger than morphine.
Prosecutors allege that from 2012 to 2015, Kapoor, Babich and others conspired to bribe doctors in exchange for prescribing Subsys. Prosecutors said they also defrauded insurers into paying for the pain treatment.
Prosecutors allege Insys paid doctors kickbacks in the form of fees to participate in speaker programs ostensibly meant to educate medical professionals about Subsys that were actually sham events.
The case is a major example of their efforts to combat the nation's opioid addiction epidemic, prosecutors said. According to the U.S. Centers for Disease Control and Prevention, opioids were involved in a record 47,600 overdose deaths in 2017.
Babich's expected plea comes after Alec Burlakoff, Insys' former vice president of sales, pleaded guilty in November and agreed to testify as a government witness.
Babich, 42, is married to a former Insys sales representative, Natalie Babich, who in 2017 pleaded guilty to conspiring to pay kickbacks and became a government witness.
She testified last month at the trial of Christopher Clough, a former physician assistant in New Hampshire accused of accepting kickbacks from Insys. A federal jury in Concord, New Hampshire convicted Clough on Dec. 18.